Reuters logo
BRIEF-Genentech says FDA advisory committee unanimously recommends approval of co’s subcutaneous rituximab for certain blood cancers
March 29, 2017 / 4:24 PM / 7 months ago

BRIEF-Genentech says FDA advisory committee unanimously recommends approval of co’s subcutaneous rituximab for certain blood cancers

March 29 (Reuters) - Genentech:

* FDA advisory committee unanimously recommends approval of Genentech’s subcutaneous rituximab for certain blood cancers

* FDA is expected to make a decision on approval for rituximab by June 26, 2017 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below